BiomX Inc.

BiomX Inc. (ticker: PHGE) is a clinical-stage biopharmaceutical company focused on developing phage-based therapies targeting chronic infectious diseases, including antibiotic-resistant bacterial infections. The company became publicly listed in 2019 through a merger with Chardan NexTech Acquisition Corp., a blank-check vehicle sponsored by Chardan Capital Markets, placing it in the life sciences and biotechnology sector. BiomX operates as a post-merger de-SPAC entity and has continued to file periodic reports with the SEC, including the Form 8-K submitted on June 20, 2023, under accession number 0001213900-23-050060. Sign up at SpacDesk for full filing history, sponsor profiles, and real-time SPAC data on BiomX and hundreds of other transactions.